释放高分子量5-HT7R配体的潜力:合成,亲和力和ADMET检查
Patryk Pyka1, Sabrina Garbo2, Aleksandra Murzyn3
1Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University, Medical College, Medyczna 9, PL 30-688 Kraków, Poland; Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-530 Kraków, Poland.
研究人员开发了针对中枢神经系统疾病的5-HT7受体的新型aryl-piperazine hydantoin配体. 一种化合物显示出有前途的类似药物的特性和治疗神经退行性疾病的潜力.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 越来越多的药物和化合物存储库需要重新验证药物财产规则.
- 开发创新的中枢神经系统 (CNS) 药物需要针对特定的受体,如5-HT7R.
- 高分子量化合物 (大约500Da) 正在探索药物开发.
研究的目的:
- 设计和合成用于5-HT7受体的新型阿里尔-皮佩拉水坦因配体.
- 评估合成的化合物对受体活性,选择性和类似药物的特性 (ADMET).
- 在神经退行细胞模型中评估化合物的潜力.
主要方法:
- 合成了14种新的阿里尔-皮佩拉水素化合物.
- 在体外查5-HT7受体亲和力和对相关受体的选择性.
- 在体外ADMET (吸收,分布,新陈代谢,分泌,毒性) 分析.
- 对接研究是为了了解结构-活动关系.
- 在阿尔茨海默氏病模型中评估基因表达特征和细胞存活率.
主要成果:
- 所有合成的化合物都对5-HT7R具有很高的亲和力 (Ki < 250 nM),具有良好的选择性.
- 化合物32表现出有利的ADMET概况:良好的膜透性,低毒性,高代谢稳定性和高血蛋白结合性.
- 化合物32个调节的基因与神经退行,抗氧化反应和炎症相关.
- 化合物32在体外阿尔茨海默病模型中改善了神经细胞的存活率.
结论:
- 针对5-HT7R的新型阿里尔-皮佩拉辛胺因被成功合成和表征.
- 化合物32是中枢神经系统疾病的有希望的候选药物,因为它具有平衡的药理和ADMET特性.
- 对化合物32的进一步优化和测试对于神经退行性疾病的潜在治疗应用是有必要的.
更多相关视频
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
10:16Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
Published on: March 12, 2019
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Ligand Binding and Linkage
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
